(CANC) Tema Oncology - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • • Health
CANC: Cancer, Treatment, Drugs, Pharmaceuticals, Biotechnology, Research
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Additional Sources for CANC ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CANC ETF Overview
| Market Cap in USD | 47m |
| Category | Health |
| TER | 0.75% |
| IPO / Inception | 2023-08-14 |
CANC ETF Ratings
| Growth 5y | 60.9% |
| Fundamental | - |
| Dividend | 72.0% |
| Rel. Strength Industry | -101 |
| Analysts | - |
| Fair Price Momentum | 23.47 USD |
| Fair Price DCF | - |
CANC Dividends
| Dividend Yield 12m | 2.89% |
| Yield on Cost 5y | 20.68% |
| Annual Growth 5y | 121.04% |
| Payout Consistency | 100.0% |
CANC Growth Ratios
| Growth Correlation 3m | -84.3% |
| Growth Correlation 12m | 0.9% |
| Growth Correlation 5y | 60.7% |
| CAGR 5y | 291.71% |
| CAGR/Mean DD 5y | 47.45 |
| Sharpe Ratio 12m | -0.13 |
| Alpha | -29.03 |
| Beta | 1.09 |
| Volatility | 22.04% |
| Current Volume | 19.4k |
| Average Volume 20d | 36.5k |
What is the price of CANC stocks?
As of January 23, 2025, the stock is trading at USD 25.23 with a total of 19,421 shares traded.
Over the past week, the price has changed by +2.79%, over one month by +2.27%, over three months by -8.24% and over the past year by -0.18%.
As of January 23, 2025, the stock is trading at USD 25.23 with a total of 19,421 shares traded.
Over the past week, the price has changed by +2.79%, over one month by +2.27%, over three months by -8.24% and over the past year by -0.18%.
Is Tema Oncology a good stock to buy?
Yes. Based on ValueRay Analyses, Tema Oncology (NASDAQ:CANC) is currently (January 2025) a good stock to buy. It has a ValueRay Growth Rating of 60.89 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CANC as of January 2025 is 23.47. This means that CANC is currently overvalued and has a potential downside of -6.98%.
Yes. Based on ValueRay Analyses, Tema Oncology (NASDAQ:CANC) is currently (January 2025) a good stock to buy. It has a ValueRay Growth Rating of 60.89 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CANC as of January 2025 is 23.47. This means that CANC is currently overvalued and has a potential downside of -6.98%.
Is CANC a buy, sell or hold?
Tema Oncology has no consensus analysts rating.
Tema Oncology has no consensus analysts rating.
What are the forecast for CANC stock price target?
According to ValueRays Forecast Model, CANC Tema Oncology will be worth about 26.2 in January 2026. The stock is currently trading at 25.23. This means that the stock has a potential upside of +3.77%.
According to ValueRays Forecast Model, CANC Tema Oncology will be worth about 26.2 in January 2026. The stock is currently trading at 25.23. This means that the stock has a potential upside of +3.77%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 26.2 | 3.8% |